In conclusion, we have successfully established two patient iPSC lines as a first step in the creation of iPSC-chondrocyte models to study and therapeutically target the disease mechanisms underlying SEMD, biglycan type. This evidence concerns the gene BGN and spondyloepimetaphyseal dysplasia.